1. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells;Bischoff;Science,1996
2. Andtbacka, R.H.I., Collichio, F.A., Amatruda, T., Senzer, N.N., Chesney, J., Delman, K.A., Spitler, L.E., Puzanov, I., Doleman, S., and Ye, Y. (2013). OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J. Clin. Oncol., 31.
3. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma;Senzer;J. Clin. Oncol.,2009
4. Oncolytics Biotech® Inc. (2015, October 09). Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Status from the EMA for Pancreatic Cancer. Available online: http://www.oncolyticsbiotech.com/news/press-release-details/2015/Oncolytics-Biotech-Inc-Announces-Receipt-of-Orphan-Drug-Status-from-the-EMA-for-Pancreatic-Cancer/default.aspx.
5. Oncolytics Biotech® Inc. (2015, October 09). Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Gastric Cancer. Available online: http://www.oncolyticsbiotech.com/news/press-release-details/2015/Oncolytics-Biotech-Inc-Announces-Receipt-of-Orphan-Drug-Designation-from-the-US-FDA-for-Gastric-Cancer/default.aspx.